1. Pregnant or nursing female. <br/ >2. Patients with history of allergy, hypersensitivity, or any serious reaction to study medication <br/ >3. Patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. <br/ >4. Patient previously enrolled into this study. <br/ >5. Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukemia or HIV. <br/ >6. Patients with a life expectancy judged to be less than five days <br/ >7. ALT/AST > 5 times the upper limit of normal <br/ >8. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >9. Patients not likely to complete the trial as per judgment of the investigator.

1. Pregnant or nursing female. <br/ >2. Patients with history of allergy, hypersensitivity, or any serious reaction to study medication <br/ >3. Patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. <br/ >4. Patient previously enrolled into this study. <br/ >5. Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukemia or HIV. <br/ >6. Patients with a life expectancy judged to be less than five days <br/ >7. ALT/AST > 5 times the upper limit of normal <br/ >8. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >9. Patients not likely to complete the trial as per judgment of the investigator.

N/A

N/A

1. Pregnant or nursing female. <br/ >2. Patients with history of allergy, hypersensitivity, or any serious reaction to study medication <br/ >3. Patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. <br/ >4. Patient previously enrolled into this study. <br/ >5. Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukemia or HIV. <br/ >6. Patients with a life expectancy judged to be less than five days <br/ >7. ALT/AST > 5 times the upper limit of normal <br/ >8. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >9. Patients not likely to complete the trial as per judgment of the investigator.

1. Pregnant or nursing female. <br/ >2. Patients with history of allergy, hypersensitivity, or any serious reaction to study medication <br/ >3. Patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. <br/ >4. Patient previously enrolled into this study. <br/ >5. Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukemia or HIV. <br/ >6. Patients with a life expectancy judged to be less than five days <br/ >7. ALT/AST > 5 times the upper limit of normal <br/ >8. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >9. Patients not likely to complete the trial as per judgment of the investigator.